A Phase 2 interventional study of SGI-110 and Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine) in Ovarian Cancer, sponsored by Astex Pharmaceuticals, Inc.. Completed at 24 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 166 studies testing carboplatin in Ovarian Neoplasms — 14 open to participants now, 21 under way, 6 of them phase 3. Carboplatin · Ovarian Neoplasms.
Among the 166 studies testing carboplatin in Ovarian Neoplasms, this one is the 39th largest by enrollment of the 150 interventional ones that give a count, is one of 4 that started in 2012, is one of 84 in phase 2, and was the 117th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →14 of the 166 studies testing carboplatin in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
CSPC Megalith Biopharmaceutical Co.,Ltd. · Sites in China
Ages 18+
Jiangsu Cancer Institute & Hospital · Sites in China
Ages 18–75
Merck Sharp & Dohme LLC · Sites in United States, Australia, Canada and 6 more countries
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Women only
Zhejiang Cancer Hospital · Sites in China
Women only
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
166 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 106 · Phase 3 28 · Phase 4 2
First in 1989; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 48 across the 150 interventional studies. Of the 117 that completed or were terminated, 38 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 166 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astex Pharmaceuticals, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Astex Pharmaceuticals, Inc. is the lead sponsor of 45 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 6 (46%) have results posted.
Otsuka Holdings Co., Ltd. has 2 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies testing carboplatin in Ovarian Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06476184Phase 3ARCAGY/ GINECO GROUPUtility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery | 2027-06 |
| NCT04520074Phase 3Fudan UniversityAdjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | 2027-09 |
| NCT05456685AbbVieMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer | 2026-11 |
| NCT07285941Zhejiang Cancer HospitalEfficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment | 2027-01-04 |
| NCT01970722City of Hope Medical CenterSurgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | 2027-01-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 166 studies testing carboplatin in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A 2-part, Phase 2 controlled, open-label, randomized study in participants with platinum-resistant recurrent ovarian cancer. In Part 1, participants received SGI-110 and carboplatin. The optimum dose of SGI-110 (guadecitabine) was identified in Part 1 based on safety and efficacy. In Part 2, participants were randomized to receive the dose identified in Part 1 plus carboplatin or one of four treatment of choice at the discretion of the investigator. The treatment of choice consisted of topotecan, pegylated liposomal doxorubicin, paclitaxel or gemcitabine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stage 1 was a safety lead-in stage with a dose escalation design. Participants were evaluated with the combination of SGI-110 (guadecitabine) plus carboplatin (G+C), given as 28-day treatment cycles: guadecitabine administered subcutaneous (SC) daily on Days 1-5, at a starting dose of 45 mg/m2/day in Cohort 1, followed by carboplatin intravenous (IV) based on a targeted dose of area under the curve (AUC) 5 on Day 8. After dose limiting toxicities were noted, guadecitabine dose was reduced to 30 mg/m2/day for subsequent cycles for 4 participants. Cohort 2 received 30 mg/m2/day guadecitabine and carboplatin IV AUC 4.
Drug: SGI-110 · Drug: Carboplatin
Stage 2 was an open-label, randomized, controlled trial. Eligible participants were randomly assigned in a 1:1 ratio to receive either (1) G+C combination treatment in 28-day cycles at 30 mg/m2 SC once daily on Days 1-5 and carboplatin IV AUC 4 on Day 8, or (2) treatment of choice (TC) of topotecan, pegylated liposomal doxorubicin (PLD), paclitaxel, or gemcitabine based on recommended dosing in 28-day cycles; participants initially randomized to TC were able to cross over to receive 30 mg/m2 G+C due to disease progression.
Drug: SGI-110 · Drug: Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine) · Drug: Carboplatin
Also known as: guadecitabine
Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
Stage 1: Dose Limiting Toxicities
Number of participants with dose limiting toxicities (DLTs) in Stage 1
Time frame: Up to 12 months
Stage 2: Progression Free Survival
Progression free survival (PFS) time was defined as the time interval from the date of the first dose of study medication until the earlier of disease progression or death. Participants were treated with their assigned treatment \[guadecitabine+carboplatin (G+C) or treatment choice (TC)\] until disease progression or unacceptable treatment-related toxicity occurred.
Time frame: Up to 24 months
Objective Response Rate
The objective response rate (ORR) was defined as the proportion of participants who experienced an objective response (best overall response of complete response/full response or partial response, which was confirmed by a subsequent assessment at least 28 days later). Response categories were determined based on RECIST v1.1 criteria, or on modified Rustin (CA-125) criteria if response assessment could not be made using RECIST criteria.
Time frame: Up to 24 months
Progression Free Survival at 6 Months
Progression free survival rate at 6 months is the proportion of participants who were alive and did not have disease progression at 6 months after start of treatment.
Time frame: 6 months
Clinical Benefit Rate
Clinical benefit rate (CBR) was defined as the proportion of subjects who experienced a best overall response of complete response/full response or partial response (confirmed by a subsequent assessment at least 28 days later), or documented stable disease for at least 3 months after the first dose. Response categories were determined based on RECIST v1.1 criteria, then based on modified Rustin (CA-125) criteria if assessment could not be made using RECIST criteria.
Time frame: Up to 24 months
CA-125 Levels
Percentage of participants with CA-125 reduction by ≥ 50% from baseline
Time frame: Up to 24 months
Duration of Response
Duration of response is defined as the time between the date of the first documentation of complete response/full response or partial response, and the date of disease progression or date of death due to any cause, or the last adequate tumor assessment prior to the start of subsequent anti-cancer therapy including crossing over to G+C from TC arm, whichever occurred earlier. Only participants who responded were included in the duration of response calculation.
Time frame: Up to 24 months
Overall Survival
Overall survival was defined as the number of days from the day the participant was administered the first dose of study treatment to the date of death (regardless of cause). Survival time was censored on the last date the participant was known to be alive or lost to follow-up before reaching the event of death; in the TC group, time was censored at the date of crossover.
Time frame: Up to 24 months
Stage 1: Pharmacokinetic Parameter Cmax
Time to maximum plasma concentration for guadecitabine, decitabine and carboplatin
Time frame: Pre-dose and up to 8 hours post-dose on Cycle 1 Day 1 for guadecitabine and decitabine and Day 8 for carboplatin (28 day cycles)
Stage 1: Pharmacokinetic Parameter Tmax
Time to last measurable concentration for guadecitabine, decitabine and carboplatin
Time frame: Pre-dose and up to 8 hours post-dose on Cycle 1 Day 1 for guadecitabine and decitabine and Day 8 for carboplatin (28 day cycles)
Stage 1: Pharmacokinetic Parameter AUC0-8
Area under the concentration-time curve from 0 to 8 hours (AUC0-8) for guadecitabine, decitabine and carboplatin
Time frame: Pre-dose and up to 8 hours post-dose on Cycle 1 Day 1 for guadecitabine and decitabine and Day 8 for carboplatin (28 day cycles)
A total of 124 participants were enrolled in the study and 120 were treated at 20 study centers, with 12 in the United States, 5 in the United Kingdom, and 3 in Canada. The enrollment period was 10 December 2012 (first participant dosed) to 12 May 2014 (last participant first dose).
| Milestone | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice |
|---|---|---|---|---|
| Started | 14 | 6 | 51 | 49 |
| Completed | 0 | 0 | 0 | 27 |
| Not completed | 14 | 6 | 51 | 22 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 2 |
| Withdrew: Death | 14 | 4 | 43 | 18 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Database lock | 0 | 1 | 7 | 2 |
Number of participants with dose limiting toxicities (DLTs) in Stage 1
| Participants | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 |
|---|---|---|
| Stage 1: Dose Limiting Toxicities | 0 | 4 |
Progression free survival (PFS) time was defined as the time interval from the date of the first dose of study medication until the earlier of disease progression or death. Participants were treated with their assigned treatment \[guadecitabine+carboplatin (G+C) or treatment choice (TC)\] until disease progression or unacceptable treatment-related toxicity occurred.
| Days | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice |
|---|---|---|
| Stage 2: Progression Free Survival | 114 (63 to 169) | 64 (52 to 105) |
The objective response rate (ORR) was defined as the proportion of participants who experienced an objective response (best overall response of complete response/full response or partial response, which was confirmed by a subsequent assessment at least 28 days later). Response categories were determined based on RECIST v1.1 criteria, or on modified Rustin (CA-125) criteria if response assessment could not be made using RECIST criteria.
| Percent | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Stage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2 |
|---|---|---|---|---|---|
| Objective Response Rate | 21 (4.7 to 50.8) | 0 (0.0 to 45.9) | 16 (7.0 to 28.6) | 8 (2.3 to 19.6) | 4 (0.1 to 19.0) |
Progression free survival rate at 6 months is the proportion of participants who were alive and did not have disease progression at 6 months after start of treatment.
| Percent of participants | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Stage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2 |
|---|---|---|---|---|---|
| Progression Free Survival at 6 Months | 0.36 (0.13 to 0.59) | 0.33 (0.05 to 0.68) | 0.37 (0.24 to 0.50) | 0.11 (0.04 to 0.22) | 0.19 (0.07 to 0.35) |
Clinical benefit rate (CBR) was defined as the proportion of subjects who experienced a best overall response of complete response/full response or partial response (confirmed by a subsequent assessment at least 28 days later), or documented stable disease for at least 3 months after the first dose. Response categories were determined based on RECIST v1.1 criteria, then based on modified Rustin (CA-125) criteria if assessment could not be made using RECIST criteria.
| Percent of participants | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Stage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2 |
|---|---|---|---|---|---|
| Clinical Benefit Rate | 43 (17.7 to 71.1) | 50 (11.8 to 88.2) | 41 (27.6 to 55.8) | 29 (16.6 to 43.3) | 19 (6.3 to 38.1) |
Percentage of participants with CA-125 reduction by ≥ 50% from baseline
| Percent of participants | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Stage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2 |
|---|---|---|---|---|---|
| CA-125 Levels | 27 (6.0 to 61.0) | 50 (6.8 to 93.2) | 36 (21.6 to 52.0) | 32 (18.1 to 48.1) | 29 (11.3 to 52.2) |
Duration of response is defined as the time between the date of the first documentation of complete response/full response or partial response, and the date of disease progression or date of death due to any cause, or the last adequate tumor assessment prior to the start of subsequent anti-cancer therapy including crossing over to G+C from TC arm, whichever occurred earlier. Only participants who responded were included in the duration of response calculation.
| Days | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Stage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2 |
|---|---|---|---|---|---|
| Duration of Response | 225 (42.0 to 294.0) | 195 (114.0 to NA) | 186 (147.0 to 241.0) | 173 (121.0 to 267.0) | 182 (147.0 to 233.0) |
Overall survival was defined as the number of days from the day the participant was administered the first dose of study treatment to the date of death (regardless of cause). Survival time was censored on the last date the participant was known to be alive or lost to follow-up before reaching the event of death; in the TC group, time was censored at the date of crossover.
| Days | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Stage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2 |
|---|---|---|---|---|---|
| Overall Survival | 341 (100.0 to 567.0) | 195 (25.0 to NA) | 331 (231 to 415) | 221 (145 to 372) | 279 (161.0 to 413.0) |
Time to maximum plasma concentration for guadecitabine, decitabine and carboplatin
| ng/mL | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 |
|---|---|---|
| Guadecitabine | 96.2 ± 78.3 | 109 ± 70.8 |
| Decitabine | 22.6 ± 13.3 | 26.3 ± 14.5 |
| Carboplatin | 19600 ± 5650 | 21900 ± 13800 |
Time to last measurable concentration for guadecitabine, decitabine and carboplatin
| Hours | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 |
|---|---|---|
| Guadecitabine | 1.42 (0.25 to 6.00) | 1.98 (1.50 to 7.25) |
| Decitabine | 1.98 (1.00 to 6.00) | 3.95 (1.67 to 7.25) |
| Carboplatin | 1.03 (0.48 to 1.20) | 1.05 (0.48 to 1.20) |
Area under the concentration-time curve from 0 to 8 hours (AUC0-8) for guadecitabine, decitabine and carboplatin
| Hours*ng/mL | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 |
|---|---|---|
| Guadecitabine | 239 ± 136 | 416 ± 217 |
| Decitabine | 71.1 ± 26.6 | 129 ± 17.9 |
| Carboplatin | 51200 ± 12100 | 41900 ± 31700 |
Collected over Approximately 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | 14/14 (100%) | 8/14 (57.1%) | 14/14 (100%) |
| Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | 4/6 (66.7%) | 4/6 (66.7%) | 6/6 (100%) |
| Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | 43/51 (84.3%) | 26/51 (51%) | 50/51 (98%) |
| Stage 2: Treatment Choice | 18/49 (36.7%) | 24/49 (49%) | 49/49 (100%) |
| Stage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2 | 22/27 (81.5%) | 12/27 (44.4%) | 27/27 (100%) |
| Event | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Stage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2 |
|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/14 | 2/6 | 1/51 | 0/49 | 1/27 |
| VomitingGastrointestinal disorders | 2/14 | 2/6 | 1/51 | 5/49 | 2/27 |
| NauseaGastrointestinal disorders | 2/14 | 2/6 | 0/51 | 2/49 | 1/27 |
| Abdominal painGastrointestinal disorders | 0/14 | 0/6 | 2/51 | 3/49 | 5/27 |
| Adverse drug reactionGeneral disorders | 0/14 | 1/6 | 0/51 | 0/49 | 0/27 |
| Mental status changePsychiatric disorders | 0/14 | 1/6 | 0/51 | 1/49 | 0/27 |
| AnemiaBlood and lymphatic system disorders | 0/14 | 1/6 | 1/51 | 1/49 | 0/27 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/14 | 1/6 | 0/51 | 0/49 | 0/27 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/14 | 1/6 | 0/51 | 2/49 | 1/27 |
| Cerebrovascular accidentNervous system disorders | 0/14 | 1/6 | 0/51 | 1/49 | 0/27 |
| Event | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Stage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2 |
|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 3/14 | 6/6 | 12/51 | 12/49 | 10/27 |
| NeutropeniaBlood and lymphatic system disorders | 7/14 | 5/6 | 36/51 | 16/49 | 18/27 |
| NauseaGastrointestinal disorders | 10/14 | 2/6 | 38/51 | 28/49 | 12/27 |
| FatigueGeneral disorders | 9/14 | 4/6 | 33/51 | 26/49 | 14/27 |
| PyrexiaGeneral disorders | 2/14 | 4/6 | 8/51 | 3/49 | 3/27 |
| AnemiaBlood and lymphatic system disorders | 7/14 | 4/6 | 16/51 | 25/49 | 8/27 |
| ConstipationGastrointestinal disorders | 5/14 | 4/6 | 22/51 | 17/49 | 10/27 |
| HypomagnesemiaMetabolism and nutrition disorders | 3/14 | 4/6 | 15/51 | 8/49 | 9/27 |
| VomitingGastrointestinal disorders | 6/14 | 2/6 | 32/51 | 15/49 | 10/27 |
| Injection site reactionGeneral disorders | 8/14 | 2/6 | 23/51 | 1/49 | 9/27 |
Includes all treated participants
| Age, Continuous(Years) | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Total |
|---|---|---|---|---|---|
| Mean | 57.99 ± 9.47 | 56.79 ± 13.20 | 61.96 ± 9.17 | 62.09 ± 9.62 | 61.29 ± 9.62 |
| Sex: Female, Male(Participants) | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Total |
|---|---|---|---|---|---|
| Female | 14 | 6 | 51 | 49 | 120 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 2 | 3 | 6 |
| Not Hispanic or Latino | 13 | 6 | 49 | 46 | 114 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Stage 1: Guadecitabine+Carboplatin 30 mg/m2 | Stage 1: Guadecitabine+Carboplatin 45 mg/m2 | Stage 2: Guadecitabine+Carboplatin 30 mg/m2 | Stage 2: Treatment Choice | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 5 | 5 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 1 | 0 | 2 | 2 | 5 |
| White | 12 | 5 | 43 | 40 | 100 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 1 | 3 |
The record gives a start of Sep 2012, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2021, 4 years 9 months after primary completion. A results delay was requested in Jan 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Guadecitabine · Carboplatin